• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Illumina appoints Ankur Dhingra Chief Financial Officer, Jakob Wedel Chief Strategy and Corporate Development Officer

    4/9/24 4:05:00 PM ET
    $ILMN
    $SMMT
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ILMN alert in real time by email

    Joydeep Goswami to serve as advisor through June 30

    Illumina reaffirms Q1 2024 and full-year 2024 financial guidance

    SAN DIEGO, April 9, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that Joydeep Goswami has decided to leave Illumina. He will stay on in an advisory role through June 30 to support two new executive management team appointments.

    Ankur Dhingra, who will become Illumina's Chief Financial Officer on April 15.

    Ankur Dhingra is joining Illumina as Chief Financial Officer (CFO), leading Illumina's financial planning and analysis, accounting, investor relations, internal audit, tax, and treasury functions. Dhingra brings a breadth of experience from the life sciences tools, diagnostics, and pharmaceutical industries. He formerly was CFO at Summit Therapeutics Inc. (NASDAQ:SMMT), and prior to that was CFO of CAREDx, Inc. Dhingra spent more than 18 years at Agilent Technologies, most recently as VP, Investor Relations. Before that, he held various finance leadership roles with progressively increasing responsibility, including multiple business unit CFO roles. He brings experience in developing and executing growth and margin improvement strategies, delivering P&L commitments, and driving businesses toward increasing levels of performance. Dhingra has a demonstrated record of success in executing and influencing growth-oriented business strategies, as well as managing global finance and accounting teams. He is a Chartered Accountant and member of The Institute of Chartered Accountants of India.

    Jakob Wedel has been named Chief Strategy and Corporate Development Officer. Wedel joined Illumina in November 2023 as CEO Chief of Staff, leading strategic transformation initiatives. In his new role, Wedel is responsible for driving Illumina's strategic planning, partnerships, and acquisitions. Previously, Wedel was partner at EY's strategy practice, co-leading their global life science practice, and served in roles at McKinsey & Company and Bain & Company. In the early 2000s, Wedel co-founded the Nordic strategy firm QVARTZ, which was later acquired by Bain.

    "I am proud of the talent joining our management team as we work to deliver on Illumina's mission to improve human health by unlocking the power of the genome," said Jacob Thaysen, Illumina CEO. "Ankur brings deep financial expertise, investor and leadership experience, and industry knowledge to Illumina's CFO role, and Jakob has keen insights gained from 25 years in strategy leadership roles with global consulting firms. Both are deeply committed to serving our customers and helping Illumina grow."

    Dhingra and Wedel are both relocating to San Diego. They succeed Goswami, who held both the CFO and Chief Strategy and Corporate Development Officer roles since early 2023. Goswami joined Illumina in 2019 to lead strategy and corporate development. He will continue as an advisor to the company starting April 15 and through June 30. He departs the organization on July 1.

    "We are grateful to Joydeep for his many contributions to Illumina over more than four years, and for most recently leading these two key functions," said Thaysen. "Joydeep will continue with us for several weeks to support a smooth leadership transition."

    The company has reaffirmed its guidance for the first quarter 2024 and full-year 2024, as announced during its fourth quarter 2023 earnings call on February 8, 2024.

    About Illumina

    Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube.

    Contacts

    Investors:

    Salli Schwartz

    858-291-6421

    [email protected]

    Media:

    David McAlpine

    347-327-1336

    [email protected]

    Jakob Wedel, who will become Illumina's Chief Strategy and Corporate Development Officer on April 15.

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/illumina-appoints-ankur-dhingra-chief-financial-officer-jakob-wedel-chief-strategy-and-corporate-development-officer-302112206.html

    SOURCE Illumina, Inc.

    Get the next $ILMN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ILMN
    $SMMT

    CompanyDatePrice TargetRatingAnalyst
    Summit Therapeutics Inc.
    $SMMT
    3/26/2025$23.00 → $35.00Neutral → Buy
    Citigroup
    Summit Therapeutics Inc.
    $SMMT
    3/21/2025Overweight
    Cantor Fitzgerald
    Summit Therapeutics Inc.
    $SMMT
    3/12/2025$30.00Outperform
    Evercore ISI
    Illumina Inc.
    $ILMN
    3/4/2025$130.00 → $90.00Neutral
    Citigroup
    Illumina Inc.
    $ILMN
    2/28/2025$100.00Buy → Hold
    HSBC Securities
    Summit Therapeutics Inc.
    $SMMT
    2/28/2025$42.00Buy
    Goldman
    Illumina Inc.
    $ILMN
    2/10/2025$130.00 → $100.00Equal Weight → Underweight
    Barclays
    Illumina Inc.
    $ILMN
    2/7/2025$177.00 → $140.00Buy → Hold
    TD Cowen
    More analyst ratings

    $ILMN
    $SMMT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Summit Therapeutics upgraded by Citigroup with a new price target

      Citigroup upgraded Summit Therapeutics from Neutral to Buy and set a new price target of $35.00 from $23.00 previously

      3/26/25 7:47:33 AM ET
      $SMMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on Summit Therapeutics

      Cantor Fitzgerald initiated coverage of Summit Therapeutics with a rating of Overweight

      3/21/25 8:11:46 AM ET
      $SMMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evercore ISI initiated coverage on Summit Therapeutics with a new price target

      Evercore ISI initiated coverage of Summit Therapeutics with a rating of Outperform and set a new price target of $30.00

      3/12/25 7:33:36 AM ET
      $SMMT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ILMN
    $SMMT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Illumina Reports Financial Results for First Quarter of Fiscal Year 2025

      Core Illumina revenue of $1.04 billion for Q1 2025, down 1% from Q1 2024 (flat on a constant currency basis)GAAP operating margin of 15.8% and non-GAAP operating margin of 20.4% for Q1 2025GAAP diluted EPS of $0.82 and non-GAAP diluted EPS of $0.97 for Q1 2025Cash provided by operations of $240 million and free cash flow of $208 million for Q1 2025For fiscal year 2025, we expect:Core Illumina revenue to decline between (1%) and (3%) on a constant currency basis year over year, down from low single digit growth previouslyRevenue outside of the Greater China region expected to grow between 0% and 2% in 2025 on a constant currency basis year over year and includes our estimate reflecting change

      5/8/25 4:13:00 PM ET
      $ILMN
      Medical Specialities
      Health Care
    • Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2025

      Ivonescimab in Combination with Chemotherapy Achieves Statistically Significant Superiority in PFS vs. Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in First-Line Treatment of Patients with Advanced Squamous NSCLC in HARMONi-6 Study Conducted by Akeso in China Enrollment Continues in Global Phase III Trial HARMONi-3 in First-Line Treatment of Patients with Metastatic NSCLC Ivonescimab Receives Approval in China as Monotherapy for First-Line Treatment for Advanced NSCLC in Tumors with Positive PD-L1 Expression: Interim Overall Survival HR = 0.777 in China for HARMONi-2 Study Conducted by Akeso Enrollment Has Begun in HARMONi-7 Global Phase III Trial in First-Line PD-L1 High, Metastatic

      5/1/25 4:09:00 PM ET
      $SMMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Illumina and Ovation.io launching first-of-kind GLP-1 dataset to accelerate new therapy development

      First real-world dataset with integrated clinical and multiomic insights from 25,000 patients treated with GLP-1 therapies Dataset will advance development of GLP-1 therapies in new indications and accelerate discovery of novel drug targets in patients who are unresponsive to therapies SAN DIEGO, May 1, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN), and Ovation.io, Inc., an organization dedicated to building best-in-class multiomics datasets, today announced the development of the largest commercially available clinical multiomic dataset from 25,000 patients treated with glucagon-like peptide-1 (GLP-1) receptor agonist therapies. The dataset will be made available to the pharma community

      5/1/25 9:15:00 AM ET
      $ILMN
      Medical Specialities
      Health Care

    $ILMN
    $SMMT
    Leadership Updates

    Live Leadership Updates

    See more

    $ILMN
    $SMMT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $ILMN
    $SMMT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Illumina Board of Directors elects Dr. Scott Gottlieb Chair, Keith Meister to join Board of Directors

      Stephen MacMillan to retire from the Board SAN DIEGO, March 25, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN), a global leader in DNA sequencing and array-based technologies, today announced changes to its Board of Directors. Scott Gottlieb, MD, has been elected non-executive Chair of Illumina's Board. Dr. Gottlieb has served on the Board of Directors since 2020. Additionally, Keith Meister, founder, Managing Partner, and Chief Investment Officer of Corvex Management, will join the Board of Directors on March 28, 2025. Stephen MacMillan, Chairman, President, and CEO of Hologic, who joined the Illumina Board in June 2023, has decided to retire from the board in preparation for the company

      3/25/25 9:00:00 AM ET
      $ILMN
      Medical Specialities
      Health Care
    • Robert LaCaze, Innovative Growth-Driver in Oncology, Joins Summit Therapeutics as Chief Commercial Officer

      Mr. LaCaze Brings Over 35 Years of Executive Leadership Experience in the Biopharmaceutical Industry Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced that Robert LaCaze has joined Summit Therapeutics as Chief Commercial Officer, reporting to Manmeet S. Soni, Chief Operating Officer and Chief Financial Officer, effective immediately. Robert W. Duggan and Dr. Maky Zanganeh, Co-CEOs of Summit Therapeutics, stated, "Robert's extensive experience and proven track record in the oncology space make him an exceptional addition to our team. His leadership will be instrumental as we seek to bring ivonescimab to patients in need. We are truly excited to have

      3/17/25 4:24:00 PM ET
      $SMMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Summit Therapeutics Appoints Jeff Huber, Transformational Google and GRAIL Executive, to its Board of Directors

      Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced that Jeff Huber has been appointed to its Board of Directors, effective immediately. "It is an honor to add Jeff Huber to our excellent, diverse group of board members," stated Robert W. Duggan, Chairman and Chief Executive Officer of Summit. "Jeff's executive leadership experience in healthcare and technology and his countless accomplishments evidence his ability to translate what's possible into transformational success. As we seek to change the standard of care for solid tumors based on the potential of ivonescimab, we are thrilled to supplement our outstanding leadership team with a board member

      6/27/24 4:15:00 PM ET
      $SMMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zanganeh Mahkam bought $411,094 worth of shares (110,321 units at $3.73), increasing direct ownership by 5% to 520,814 units (SEC Form 4)

      4 - Summit Therapeutics Inc. (0001599298) (Issuer)

      3/27/24 8:28:30 PM ET
      $SMMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dhingra Ankur bought $375,000 worth of shares (100,000 units at $3.75) (SEC Form 4)

      4 - Summit Therapeutics Inc. (0001599298) (Issuer)

      3/27/24 8:27:03 PM ET
      $SMMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Thaysen Jacob bought $991,672 worth of shares (7,330 units at $135.29), increasing direct ownership by 97% to 14,861 units (SEC Form 4)

      4 - ILLUMINA, INC. (0001110803) (Issuer)

      2/26/24 8:57:29 AM ET
      $ILMN
      Medical Specialities
      Health Care
    • SVP, Strategy/Corp Development Wedel Christensen Jakob covered exercise/tax liability with 384 shares and returned $42,388 worth of shares to the company (549 units at $77.21), decreasing direct ownership by 7% to 11,808 units (SEC Form 4)

      4 - ILLUMINA, INC. (0001110803) (Issuer)

      5/7/25 4:09:16 PM ET
      $ILMN
      Medical Specialities
      Health Care
    • SEC Form 4 filed by Chief Accounting Officer Anand Bhaskar

      4 - Summit Therapeutics Inc. (0001599298) (Issuer)

      5/1/25 6:17:22 PM ET
      $SMMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by COO and CFO Soni Manmeet Singh

      4 - Summit Therapeutics Inc. (0001599298) (Issuer)

      5/1/25 6:13:55 PM ET
      $SMMT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ILMN
    $SMMT
    SEC Filings

    See more
    • Illumina Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - ILLUMINA, INC. (0001110803) (Filer)

      5/8/25 4:24:10 PM ET
      $ILMN
      Medical Specialities
      Health Care
    • SEC Form 10-Q filed by Summit Therapeutics Inc.

      10-Q - Summit Therapeutics Inc. (0001599298) (Filer)

      5/1/25 4:11:31 PM ET
      $SMMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Summit Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Summit Therapeutics Inc. (0001599298) (Filer)

      5/1/25 4:10:10 PM ET
      $SMMT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ILMN
    $SMMT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Illumina Inc.

      SC 13G/A - ILLUMINA, INC. (0001110803) (Subject)

      12/6/24 10:11:24 AM ET
      $ILMN
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by Illumina Inc.

      SC 13G - ILLUMINA, INC. (0001110803) (Subject)

      12/5/24 7:27:01 PM ET
      $ILMN
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Illumina Inc.

      SC 13G/A - ILLUMINA, INC. (0001110803) (Subject)

      11/12/24 3:59:44 PM ET
      $ILMN
      Medical Specialities
      Health Care

    $ILMN
    $SMMT
    Financials

    Live finance-specific insights

    See more
    • Illumina Reports Financial Results for First Quarter of Fiscal Year 2025

      Core Illumina revenue of $1.04 billion for Q1 2025, down 1% from Q1 2024 (flat on a constant currency basis)GAAP operating margin of 15.8% and non-GAAP operating margin of 20.4% for Q1 2025GAAP diluted EPS of $0.82 and non-GAAP diluted EPS of $0.97 for Q1 2025Cash provided by operations of $240 million and free cash flow of $208 million for Q1 2025For fiscal year 2025, we expect:Core Illumina revenue to decline between (1%) and (3%) on a constant currency basis year over year, down from low single digit growth previouslyRevenue outside of the Greater China region expected to grow between 0% and 2% in 2025 on a constant currency basis year over year and includes our estimate reflecting change

      5/8/25 4:13:00 PM ET
      $ILMN
      Medical Specialities
      Health Care
    • Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2025

      Ivonescimab in Combination with Chemotherapy Achieves Statistically Significant Superiority in PFS vs. Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in First-Line Treatment of Patients with Advanced Squamous NSCLC in HARMONi-6 Study Conducted by Akeso in China Enrollment Continues in Global Phase III Trial HARMONi-3 in First-Line Treatment of Patients with Metastatic NSCLC Ivonescimab Receives Approval in China as Monotherapy for First-Line Treatment for Advanced NSCLC in Tumors with Positive PD-L1 Expression: Interim Overall Survival HR = 0.777 in China for HARMONi-2 Study Conducted by Akeso Enrollment Has Begun in HARMONi-7 Global Phase III Trial in First-Line PD-L1 High, Metastatic

      5/1/25 4:09:00 PM ET
      $SMMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Summit Therapeutics to Host First Quarter 2025 Financial Results & Operational Progress Call on May 1, 2025

      Conference Call to be Held at 4:30pm ET Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") will host an earnings call to announce its first quarter 2025 financial results and provide an operational update for the Company on Thursday, May 1, 2025, after the market closes. Summit will host a live webcast of the earnings conference call at 4:30pm ET, which will be accessible through our website, www.smmttx.com. An archived edition of the session will be available on our website. About Summit Therapeutics Summit Therapeutics Inc. is a biopharmaceutical oncology company focused on the discovery, development, and commercialization of patient-, physician-, caregiver- and

      4/24/25 4:15:00 PM ET
      $SMMT
      Biotechnology: Pharmaceutical Preparations
      Health Care